REPRESENTATION AND EQUITY IN UTILITY ASSESSMENTS USED FOR COST-EFFECTIVENESS ANALYSES

被引：0
|
作者：
Predmore, Z. [1 ]
Huilgol, S. [1 ]
Frank, L. [2 ]
Concannon, T. [1 ]
机构：
[1] RAND Corp, Boston, MA 02116 USA
[2] RAND Corp, Santa Monica, CA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR75
引用
收藏
页码：S479 / S479
页数：1
相关论文
共 50 条
  • [1] The "e" In Cost-Effectiveness Analyses: Efficacy Or Effectiveness Of Asthma Medications Used In Cost-Effectiveness Analyses?
    Dilokthornsakul, P.
    Chaiyakunapruk, N.
    Campbell, J. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [2] Power assessments and confidence intervals for cost-effectiveness analyses
    Gardiner, JC
    Huebner, M
    Jetton, J
    MEDICAL DECISION MAKING, 1998, 18 (04) : 465 - 465
  • [3] Cost-Effectiveness and Cost-Utility Analyses of Antireflux Medicine
    Gockel, Ines
    Lange, Undine Gabriele
    Schuermann, Olaf
    Jansen-Winkeln, Boris
    Sibbel, Rainer
    Lyros, Orestis
    von dercks, Nikolaus
    GESUNDHEITSWESEN, 2019, 81 (12) : 1048 - 1056
  • [4] Subgroup analyses in cost-effectiveness analyses to support health technology assessments
    Fletcher, Christine
    Chuang-Stein, Christy
    Paget, Marie-Ange
    Reid, Carol
    Hawkins, Neil
    PHARMACEUTICAL STATISTICS, 2014, 13 (04) : 265 - 274
  • [5] The Adoption of Cost-Effectiveness Acceptability Curves in Cost-Utility Analyses
    Meckley, Lisa M.
    Greenberg, Dan
    Cohen, Joshua T.
    Neumann, Peter J.
    MEDICAL DECISION MAKING, 2010, 30 (03) : 314 - 319
  • [6] COST-EFFECTIVENESS ANALYSES
    STEINBERG, EP
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (02): : 123 - 123
  • [7] Cost-benefit, cost-effectiveness and cost-utility analyses of periodontitis prevention
    Braegger, U
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2005, 32 : 301 - 313
  • [8] Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review
    Ward, Thomas
    Mujica-Mota, Ruben E.
    Spencer, Anne E.
    Medina-Lara, Antonieta
    PHARMACOECONOMICS, 2022, 40 (01) : 45 - 64
  • [9] Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review
    Thomas Ward
    Ruben E. Mujica-Mota
    Anne E. Spencer
    Antonieta Medina-Lara
    PharmacoEconomics, 2022, 40 : 45 - 64
  • [10] Implications of Diminishing Lifespan Marginal Utility for Valuing Equity in Cost-Effectiveness Analysis
    Braithwaite, R. Scott
    MDM POLICY & PRACTICE, 2025, 10 (01)
12345